Clinical Notes: Yervoy Falls Short in Prostate Ca Trial

(MedPage Today) -- Ipilimumab (Yervoy) failed to improve overall survival when combined with radiation in patients with advanced prostate cancer, researchers said. Also this week: Sanofi pulls lixisenatide application.

Full Story →